Speedy FDA Review- Quicker Relief?

Some cancer drugs get “fast track” review by the FDA due to the urgency of the diseases they are designed to treat. Two new pieces of legislation- FAST and TREAT, seek to extend which diseases are entitled for expedited review. Neuralstem CEO says that for ALS, it’s about time (see: http://thehill.com/blogs/congress-blog/healthcare/216787-new-hope-for-our-toughest-diseases), but key leaders at FDA respond that unfortunately it isn’t that simple.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail